•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.RHHBY Secures FDA Approval for Breast Cancer Treatment
Roche Secures First U.S. Approval for New Breast-Cancer Pill
FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer
FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
US FDA approves Roche's oral treatment for advanced breast cancer
Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories
Chances of Jensen Huang returning to Nvidia 'very slim': David Roche
Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
Perficient Expands Its Innovation Center to Advance Roche Diagnostics' Molecular Laboratory Systems
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs
Roche: Valuation Leaves Limited Upside
Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors
Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma
Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories
Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
Breakfast News: Science Strikes Back at Cancer
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
Roche says divarasib cut risk of death 44% in lung cancer trial
Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Already premium?